These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 33446243)

  • 1. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.
    Behl T; Kaur G; Fratila O; Buhas C; Judea-Pusta CT; Negrut N; Bustea C; Bungau S
    Transl Neurodegener; 2021 Jan; 10(1):4. PubMed ID: 33446243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [GBA mutations and Parkinson's disease].
    Wang DX; Xie JX; Song N
    Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gaucher-Associated Parkinsonism.
    Li Y; Li P; Liang H; Zhao Z; Hashimoto M; Wei J
    Cell Mol Neurobiol; 2015 Aug; 35(6):755-61. PubMed ID: 25820783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase and Parkinson disease: Recent advances.
    Schapira AH
    Mol Cell Neurosci; 2015 May; 66(Pt A):37-42. PubMed ID: 25802027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
    Barkhuizen M; Anderson DG; Grobler AF
    Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Riboldi GM; Di Fonzo AB
    Cells; 2019 Apr; 8(4):. PubMed ID: 31010158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
    Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
    J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Smith L; Schapira AHV
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease.
    Neumann J; Bras J; Deas E; O'Sullivan SS; Parkkinen L; Lachmann RH; Li A; Holton J; Guerreiro R; Paudel R; Segarane B; Singleton A; Lees A; Hardy J; Houlden H; Revesz T; Wood NW
    Brain; 2009 Jul; 132(Pt 7):1783-94. PubMed ID: 19286695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase and parkinsonism: lessons to learn.
    Marković I; Kresojević N; Kostić VS
    J Neurol; 2016 May; 263(5):1033-1044. PubMed ID: 26995357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.
    Balestrino R; Schapira AHV
    Neuroscientist; 2018 Oct; 24(5):540-559. PubMed ID: 29400127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
    Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
    J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
    Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
    Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
    Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
    Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
    Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications.
    Zheng W; Fan D
    Front Aging Neurosci; 2022; 14():851135. PubMed ID: 35401150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between ß-glucocerebrosidase mutations and parkinsonism.
    Swan M; Saunders-Pullman R
    Curr Neurol Neurosci Rep; 2013 Aug; 13(8):368. PubMed ID: 23812893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
    Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
    Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.